Aims

To build a transnational European network for pain-insensitivity disorders.
To improve patients’ access to care, diagnostics and relevant information.
To streamline genetic testing and accelerate gene discovery.
To use omics and patient-specific cellular models to validate genetic variants.
To understand pathomechanisms and pave the way for preclinical experimental treatment trials and clinical research.